Abstract
Purpose
Use of complementary and alternative medicine (CAM) is common among breast cancer patients, but less is known about whether CAM influences breast cancer survival.
Methods
Health Eating, Activity, and Lifestyle (HEAL) Study participants (n = 707) were diagnosed with stage I–IIIA breast cancer. Participants completed a 30-month post-diagnosis interview including questions on CAM use (natural products such as dietary and botanical supplements, alternative health practices, and alternative medical systems), weight, physical activity, and comorbidities. Outcomes were breast cancer-specific and total mortality, which were ascertained from the Surveillance Epidemiology and End Results registries in Western Washington, Los Angeles County, and New Mexico. Cox proportional hazards regression models were fit to data to estimate hazard ratios (HR) and 95 % confidence intervals (CI) for mortality. Models were adjusted for potential confounding by sociodemographic, health, and cancer-related factors.
Results
Among 707 participants, 70 breast cancer-specific deaths and 149 total deaths were reported. 60.2 % of participants reported CAM use post-diagnosis. The most common CAM were natural products (51 %) including plant-based estrogenic supplements (42 %). Manipulative and body-based practices and alternative medical systems were used by 27 and 13 % of participants, respectively. No associations were observed between CAM use and breast cancer-specific (HR 1.04, 95 % CI 0.61–1.76) or total mortality (HR 0.91, 95 % CI 0.63–1.29).
Conclusion
Complementary and alternative medicine use was not associated with breast cancer-specific mortality or total mortality. Randomized controlled trials may be needed to definitively test whether there is harm or benefit from the types of CAM assessed in HEAL in relation to mortality outcomes in breast cancer survivors.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29
Demark-Wahnefried W, Clipp EC, Lipkus IM et al (2007) Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol 25(19):2709–2718
Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ (2003) Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103(3):323–328
Adams RN, Mosher CE, Blair CK, Snyder DC, Sloane R, Demark-Wahnefried W (2015) Cancer survivors’ uptake and adherence in diet and exercise intervention trials: an integrative data analysis. Cancer 121(1):77–83
Demark-Wahnefried W, Rogers LQ, Alfano CM et al (2015) Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin 65(3):167–189
Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340(22):1733–1739
Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280(18):1569–1575
Mao JJ, Palmer SC, Straton JB et al (2008) Cancer survivors with unmet needs were more likely to use complementary and alternative medicine. J Cancer Surviv 2(2):116–124
Matthews AK, Sellergren SA, Huo D, List M, Fleming G (2007) Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13(5):555–562
Wanchai A, Armer JM, Stewart BR (2010) Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs 14(4):E45–E55
Hedderson MM, Patterson RE, Neuhouser ML et al (2004) Sex differences in motives for use of complementary and alternative medicine among cancer patients. Altern Ther Health Med 10(5):58–64
Patterson RE, Neuhouser ML, Hedderson MM et al (2002) Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8(4):477–485
McLay JS, Stewart D, George J, Rore C, Heys SD (2012) Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? Eur J Clin Pharmacol 68(5):811–819
Pedersen CG, Christensen S, Jensen AB, Zachariae R (2009) Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer. Eur J Cancer 45(18):3172–3181
Rebbeck TR, Troxel AB, Norman S et al (2007) A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer 120(7):1523–1528
Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J (2006) Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 145(12):869–879
McTiernan A, Rajan KB, Tworoger SS et al (2003) Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21(10):1961–1966
Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160(7):953–958
Wayne SJ, Neuhouser ML, Koprowski C et al (2009) Breast cancer survivors who use estrogenic botanical supplements have lower serum estrogen levels than non users. Breast Cancer Res Treat 117(1):111–119
Ma H, Sullivan-Halley J, Smith AW et al (2011) Estrogenic botanical supplements, health-related quality of life, fatigue, and hormone-related symptoms in breast cancer survivors: a HEAL study report. BMC Complement Altern Med 11:109
Gruendwald J, Brendler T, Jaenicke C (2007) Physician’s desk reference for herbal products, 4th edn. Thompson Healthcare, Montvale
Cassileth BRLC (2003) Herb-drug interactions in oncology. BC Decker I, New York
Natural medicine comprehensive database (2007). www.naturaldatabase.com Accessed 11 Jun 2006
Harlan LC, Klabunde CN, Ambs AH et al (2009) Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv 3(2):89–98
Villasenor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL study. J Cancer Surviv 6(4):398–406
George SM, Irwin ML, Smith AW et al (2011) Postdiagnosis diet quality, the combination of diet quality and recreational physical activity, and prognosis after early-stage breast cancer. Cancer Causes Control 22(4):589–598
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
Greenlee H, Kwan ML, Ergas IJ et al (2014) Changes in vitamin and mineral supplement use after breast cancer diagnosis in the pathways study: a prospective cohort study. BMC Cancer 14:382
John GM, Hershman DL, Falci L, Shi Z, Tsai WY, Greenlee H (2016) Complementary and alternative medicine use among US cancer survivors. J Cancer Surviv. doi:10.1007/s11764-016-0530-y
Greenlee H, Kwan ML, Ergas IJ et al (2009) Complementary and alternative therapy use before and after breast cancer diagnosis: the pathways study. Breast Cancer Res Treat 117(3):653–665
Wyatt G, Sikorskii A, Rahbar MH, Victorson D, Adams L (2010) Intervention fidelity: aspects of complementary and alternative medicine research. Cancer Nurs 33(5):331–342
Roberts H (2010) Safety of herbal medicinal products in women with breast cancer. Maturitas 66(4):363–369
Greenlee H, Balneaves LG, Carlson LE et al (2014) Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr 2014(50):346–358
Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741
Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269
Chirgwin JH, Giobbie-Hurder A, Coates AS et al (2016) Treatment adherence and its impact on disease-free survival in the breast international group 1–98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. doi:10.1200/JCO.2015.63.8619
Dai Q, Franke AA, Yu H et al (2003) Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiol Biomark Prev 12(6):497–502
Allred CD, Ju YH, Allred KF, Chang J, Helferich WG (2001) Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis 22(10):1667–1673
Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG (2002) Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62(9):2474–2477
Greenlee H, Neugut AI, Falci L et al (2016) Association between complementary and alternative medicine use and breast cancer chemotherapy initiation: the Breast Cancer Quality of Care (BQUAL) study. JAMA Oncol 2(9):1170–1176
Ma H, Carpenter CL, Sullivan-Halley J, Bernstein L (2011) The roles of herbal remedies in survival and quality of life among long-term breast cancer survivors-results of a prospective study. BMC Cancer 11:222
Caan BJ, Natarajan L, Parker B et al (2011) Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomark Prev 20(5):854–858
Shu XO, Zheng Y, Cai H et al (2009) Soy food intake and breast cancer survival. JAMA 302(22):2437–2443
Bright-Gbebry M, Makambi KH, Rohan JP et al (2011) Use of multivitamins, folic acid and herbal supplements among breast cancer survivors: the black women’s health study. BMC Complement Altern Med 11:30
Greenlee H, Kwan ML, Kushi LH et al (2012) Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. Cancer 118(8):2048–2058
Nechuta S, Lu W, Chen Z et al (2011) Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomark Prev 20(2):262–271
Hietala M, Henningson M, Ingvar C, Jonsson PE, Rose C, Jernstrom H (2011) Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden. Acta Oncol 50(1):134–143
Han E, Johnson N, DelaMelena T, Glissmeyer M, Steinbock K (2011) Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol 18(4):912–916
Hathcock J (2001) Dietary supplements: how they are used and regulated. J Nutr 131(3s):1114S–1117S
Funding
The HEAL study was funded by National Cancer Institute (N01-CN-75036-20), N01-CN-05228, N01-PC-67010, National Institutes of Health M01-RR-00037), University of New Mexico NCRR M01-RR-0997, California Department of Health Services 050Q-8709-S1528.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Human participants
The HEAL study complied with all federal regulations for human subjects research.
Informed consent
All participating institutions have approved and on-going IRB files and all participants signed written informed consent.
Rights and permissions
About this article
Cite this article
Neuhouser, M.L., Smith, A.W., George, S.M. et al. Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study. Breast Cancer Res Treat 160, 539–546 (2016). https://doi.org/10.1007/s10549-016-4010-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-016-4010-x